<DOC>
	<DOCNO>NCT00148941</DOCNO>
	<brief_summary>`` The aim trial demonstrate consistency three manufacture lot GSK Biologicals ' DTaP-IPV candidate vaccine term immunogenicity evaluate non-inferiority GSK Biologicals ' DTaP-IPV vaccine respect immunogenicity safety compare control vaccine ( separate injection GSK Biologicals ' DTaP vaccine [ Infanrix ] Aventis Pasteur 's IPV vaccine [ IPOL ] ) administer 5th dose DTaP 4th dose inactivate poliovirus vaccine subject 4 6 year age . Vaccines co-administered second dose M-M-RII , recommend age . Concomitant administration US-licensed influenza vaccine allow accord seasonal availability vaccine discretion investigator . ''</brief_summary>
	<brief_title>Immune Response &amp; Safety Comparison 3 Lots GSK Biologicals ' DTaP-IPV Candidate Vaccine DTaP + IPV Vaccine .</brief_title>
	<detailed_description>- Investigational group : 3 , receive one 3 lot DTaP-IPV vaccine . - Control : US-licensed DTaP ( Infanrix ) + US-licensed IPV ( IPOL ) vaccine administer separate injection . - Two study visit one month apart subset subject ( Safety Immunogenicity subset ) blood draw visit . All subject one visit . - A telephone contact 4-6 day vaccination subject , telephone contact 31-38 day vaccination Safety subset telephone contact subject extend safety follow-up phase ( 5 month follow active phase ) .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female child include 4 6 year age time vaccination . Subjects receive 4 dos GSK DTaP ( primary vaccination course booster dose second year life ) 3 dos IPV first 2 year life vaccination measles , mumps , rubella second year life . Use investigational nonregistered drug vaccine study vaccine within 30 day precede administration study vaccine , plan use study period . Administration plan administration vaccine foreseen study protocol within 30 day study vaccination end Day 30 . Chronic administration plan administration immunosuppressant immune modify drug within six month prior study vaccination plan administration study period . Administration immunoglobulins and/or blood product within 3 month prior vaccination plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>